下一个修美乐藏不住了

药智网
Aug 08

一款超级大单品向来是可遇而不可求,想要找到下一个修美乐绝非易事。但艾伯维是幸运的。修美乐留下的200亿美元巨坑,眼看就要被自家的自免双星Skyrizi和Rinvoq填上了。二季度,Skyrizi全球销售额44亿美元,Rinvoq 20亿美元,继续增长强劲,两者今年合计销售额有望超过250亿美元,远高于艾伯维年初的预期。基于此,艾伯维将Skyrizi的2025年销售预期上调至171亿美,同比增长...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10